Alexion Pharmaceuticals which makes Eculizumab plan to to buy Synageva BioPharma Corp.
The drug is being studied to facilitate kidney transplants (& prevent rejection), Neuromyelitis optica & Myasthenia Gravis.
Source:
USA Today and http://alxn.com/research-development/alexion-research/soliris